Sequana Medical NV (EBR:SEQUA)

Market Cap	63.91M
Revenue (ttm)	105.50K
Net Income (ttm)	-44.65M
Shares Out	60.40M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,086
Average Volume	275,708
Open	1.086
Previous Close	1.070
Day's Range	1.052 - 1.086
52-Week Range	0.471 - 4.390
Beta	-0.06
RSI	46.26
Earnings Date	Sep 8, 2025

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 48
• Stock Exchange: Euronext Brussels
• Ticker Symbol: SEQUA

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.